Edgewise Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
EWTX Nasdaq 8731 https://edgewisetx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Edgewise Therapeutics Inc

Edgewise Therapeutics to Present on EDG-5506 for Becker Muscular Dystrophy at the 28th International Annual Congress of the World Muscle Society - Sep 27th, 2023 12:00 pm
Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker) - Sep 26th, 2023 12:00 pm
Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction - Sep 14th, 2023 12:00 pm
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 327.91%: Read This Before Placing a Bet - Sep 5th, 2023 1:55 pm
11 Cheap Small-Cap Stocks to Buy Before the Next Breakout - Sep 1st, 2023 2:12 am
Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 224.25%: Here's is How to Trade - Aug 16th, 2023 1:55 pm
Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights - Aug 10th, 2023 12:00 pm
We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely - Jul 17th, 2023 4:51 pm
Edgewise Therapeutics Touts Positive Data From Investigational Drug In Form Of Muscular Dystrophy - Jun 27th, 2023 1:43 pm
Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) - Jun 26th, 2023 8:01 pm
Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference - Jun 6th, 2023 12:00 pm
Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights - May 11th, 2023 12:00 pm
Edgewise Therapeutics to Present at Upcoming Investor Conferences - May 2nd, 2023 12:00 pm
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD) - Mar 30th, 2023 8:01 pm
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023 - Mar 21st, 2023 12:00 pm
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference - Mar 14th, 2023 12:00 pm
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors - Mar 6th, 2023 1:00 pm
Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023 - Mar 1st, 2023 1:00 pm
Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology - Feb 28th, 2023 1:00 pm
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights - Feb 23rd, 2023 1:00 pm